Skip to content
Baret News – Lifestyle
Author:
Kyverna Therapeutics, Inc.
Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
August 11, 2026
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
July 27, 2026
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition
June 22, 2026
Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
June 3, 2026
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
May 21, 2026
Kyverna Therapeutics to Present at Upcoming Investor Conferences
May 21, 2026
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
May 20, 2026
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
May 4, 2026
Yum China Reports First Quarter 2026 Results
April 29, 2026
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
April 20, 2026
1
2
Next Page
→